Mental Health Prescribers’ Perceptions on the Use of Pharmacogenetic Testing in the Management of Depression in the Middle East and North Africa Region

References

• Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–627. doi:10.1001/archpsyc.62.6.617
   PubMed Web of Science ®Google Scholar
• World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. World Health Organization; 2017.
   Google Scholar
• Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease study. J Psychiatr Res. 2020;126:134–140. doi:10.1016/j.jpsychires.2019.08.002
   PubMed Web of Science ®Google Scholar
• Ghuloum S, Bener A, Abou-Saleh MT. Prevalence of mental disorders in adult population attending primary health care setting in Qatari population. J Pak Med Assoc. 2011;61(3):216–221.
   PubMed Web of Science ®Google Scholar
• Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53. doi:10.1001/jama.2009.1943
   PubMed Web of Science ®Google Scholar
• Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449–459. doi:10.1007/s11920-007-0061-3
   PubMedGoogle Scholar
• Kim JM, Kim SW, Stewart R, et al. Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study. Hum Psychopharmacol. 2011;26(1):41–50. doi:10.1002/hup.1168
   PubMed Web of Science ®Google Scholar
• Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016;26(6):979–993. doi:10.1016/j.euroneuro.2016.03.007
   PubMed Web of Science ®Google Scholar
• Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–1070. doi:10.4088/jcp.v68n0713
   PubMed Web of Science ®Google Scholar
• Tambe V, Sirsat B, Rajpoot K, Gadeval A, Tekade RK. Chapter 11 - Pharmacogenomics and drug metabolism. In: Tekade RK, editor. Biopharmaceutics and Pharmacokinetics Considerations. Academic Press; 2021:355–385.
   Google Scholar
• Katara P, Yadav A. Pharmacogenes (PGx-genes): current understanding and future directions. Gene. 2019;718:144050. doi:10.1016/j.gene.2019.144050
   PubMed Web of Science ®Google Scholar
• Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127–134. doi:10.1002/cpt.147
   PubMed Web of Science ®Google Scholar
• Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet. 1999;56(4):247–258. doi:10.1034/j.1399-0004.1999.560401.x
   PubMed Web of Science ®Google Scholar
• Tansey KE, Guipponi M, Hu X, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry. 2013;73(7):679–682. doi:10.1016/j.biopsych.2012.10.030
   PubMed Web of Science ®Google Scholar
• Haga SB, Moaddeb J. Comparison of delivery strategies for pharmacogenetic testing services. Pharmacogenet Genomics. 2014;24(3):139–145. doi:10.1097/fpc.0000000000000028
   PubMed Web of Science ®Google Scholar
• Pagon RA, Hanson NB, Neufeld-Kaiser W, Covington ML. Genetic testing. West J Med. 2001;174(5):344–347. doi:10.1136/ewjm.174.5.344
   PubMedGoogle Scholar
• Aboelbaha S, Zolezzi M, Elewa H. Effect of pharmacogenetic-based decision support tools in improving depression outcomes: a systematic review. Neuropsychiatr Dis Treat. 2021;17:2397–2419. doi:10.2147/ndt.S312966
   PubMed Web of Science ®Google Scholar
• Brown LC, Stanton JD, Bharthi K, Maruf AA, Müller DJ, Bousman CA. Pharmacogenomic testing and depressive symptom remission: a systematic review and meta-analysis of prospective, controlled clinical trials. Clin Pharmacol Ther. 2022;112(6):1303–1317. doi:10.1002/cpt.2748
   PubMed Web of Science ®Google Scholar
• Bunka M, Wong G, Kim D, et al. Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: a rapid review and meta-analysis. Psychiatry Res. 2023;321:115102. doi:10.1016/j.psychres.2023.115102
   PubMed Web of Science ®Google Scholar
• Skryabin V, Rozochkin I, Zastrozhin M, et al. Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder. Pharmacogenomics J. 2022;2022. doi:10.1038/s41397-022-00295-3
   Google Scholar
• Pinzón-Espinosa J, van der Horst M, Zinkstok J, et al. Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians’ attitudes to sociocultural differences between patients across the globe. Transl Psychiatry. 2022;12(1):442. doi:10.1038/s41398-022-02203-6
   PubMed Web of Science ®Google Scholar
• Jameson A, Fylan B, Bristow GC, et al. What are the barriers and enablers to the implementation of pharmacogenetic testing in mental health care settings? Front Genet. 2021;12:740216. doi:10.3389/fgene.2021.740216
   PubMed Web of Science ®Google Scholar
• Virelli CR, Mohiuddin AG, Kennedy JL. Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis. Transl Psychiatry. 2021;11(1):509. doi:10.1038/s41398-021-01600-7
   PubMed Web of Science ®Google Scholar
• Vest BM, Wray LO, Brady LA, et al. Primary care and mental health providers’ perceptions of implementation of pharmacogenetics testing for depression prescribing. BMC Psychiatry. 2020;20(1):518. doi:10.1186/s12888-020-02919-z
   PubMed Web of Science ®Google Scholar
• Slomp C, Morris E, Edwards L, et al. Pharmacogenomic Testing for Major Depression: a Qualitative Study of the Perceptions of People with Lived Experience and Professional Stakeholders. Can J Psychiatry. 2022:07067437221140383. doi:10.1177/07067437221140383
   Web of Science ®Google Scholar
• Chan CY, Chua BY, Subramaniam M, Suen EL, Lee J. Clinicians’ perceptions of pharmacogenomics use in psychiatry. Pharmacogenomics. 2017;18(6):531–538. doi:10.2217/pgs-2016-0164
   PubMed Web of Science ®Google Scholar
• Shishko I, Almeida K, Silvia RJ, Tataronis GR. Psychiatric pharmacists’ perception on the use of pharmacogenomic testing in the mental health population. Pharmacogenomics. 2015;16(9):949–958. doi:10.2217/pgs.15.22
   PubMed Web of Science ®Google Scholar
• Elewa H, Alkhiyami D, Alsahan D, Abdel-Aziz A. A survey on the awareness and attitude of pharmacists and doctors towards the application of pharmacogenomics and its challenges in Qatar. J Eval Clin Pract. 2015;21(4):703–709. doi:10.1111/jep.12372
   PubMed Web of Science ®Google Scholar
• Rahma AT, Elbarazi I, Ali BR, Patrinos GP, Ahmed LA, Al-Maskari F. Stakeholders’ interest and attitudes toward genomic medicine and pharmacogenomics implementation in the United Arab emirates: a qualitative study. Public Health Genomics. 2021;24(3–4):99–109. doi:10.1159/000513753
   PubMed Web of Science ®Google Scholar
• Algahtani M. Knowledge, perception, and application of pharmacogenomics among hospital pharmacists in Saudi Arabia. Risk Manag Healthc Policy. 2020;13:1279–1291. doi:10.2147/rmhp.S267492
   PubMed Web of Science ®Google Scholar
• Muflih S, Alshogran OY, Al-Azzam S, Al-Taani G, Khader YS. Physicians‘knowledge and attitudes regarding point-of-care pharmacogenetic testing: a hospital-based cross-sectional study. Pharmgenomics Pers Med. 2021;14:655–665. doi:10.2147/pgpm.S307694
   PubMed Web of Science ®Google Scholar
• Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893–1907. doi:10.1007/s11135-017-0574-8
   PubMed Web of Science ®Google Scholar
• Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: a systematic review of empirical tests. Soc Sci Med. 2022;292:114523. doi:10.1016/j.socscimed.2021.114523
   PubMed Web of Science ®Google Scholar
• Yau A, Husain R, Haque M. A systematic review of knowledge, attitude and practice towards pharmacogenomics among doctors. Int J Pharm Res. 2015;7:9–16.
   Google Scholar
• Bannur Z, Bahaman S, Salleh M, Teh L. Pharmacogenomics based practice in Malaysia: the attitude, knowledge and adoption by the healthcare professionals. IIUM Med J Malays. 2014;13:1.
   Google Scholar
• Jessel CD, Al Maruf A, Oomen A, Arnold PD, Bousman CA. Pharmacogenetic testing knowledge and attitudes among pediatric psychiatrists and pediatricians in Alberta, Canada. J Can Acad Child Adolesc Psychiatry. 2022;31(1):18–27.
   PubMedGoogle Scholar
• Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013;23(10):535–548. doi:10.1097/FPC.0b013e3283649b9a
   PubMed Web of Science ®Google Scholar
• Winner JG, Dechairo B. Combinatorial versus individual gene pharmacogenomic testing in mental health: a perspective on context and implications on clinical utility. Yale J Biol Med. 2015;88(4):375–382.
   PubMedGoogle Scholar
• Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry. 2016;3(6):585–590. doi:10.1016/S2215-0366(16)00017-1
   PubMed Web of Science ®Google Scholar
• Curtis-Barton MT, Eagles JM. Factors that discourage medical students from pursuing a career in psychiatry. Psychiatrist. 2011;35(11):425–429. doi:10.1192/pb.bp.110.032532
   Google Scholar
• Seow LSE, Chua BY, Mahendran R, et al. Psychiatry as a career choice among medical students: a cross-sectional study examining school-related and non-school factors. BMJ Open. 2018;8(8):e022201. doi:10.1136/bmjopen-2018-022201
   PubMed Web of Science ®Google Scholar
• Lilienfeld SO. Introduction to special section on pseudoscience in psychiatry. Can J Psychiatry. 2015;60(12):531–533. doi:10.1177/070674371506001202
   PubMed Web of Science ®Google Scholar
• Choudry A, Farooq S. Systematic review into factors associated with the recruitment crisis in psychiatry in the UK: students’, trainees’ and consultants’ views. BJPsych Bull. 2017;41(6):345–352. doi:10.1192/pb.bp.116.055269
   PubMedGoogle Scholar
• Bousman CA, Dunlop BW. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J. 2018;18(5):613–622. doi:10.1038/s41397-018-0027-3
   PubMed Web of Science ®Google Scholar
• Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215–223. doi:10.1038/gim.2016.87
   PubMed Web of Science ®Google Scholar
• Caudle KE, Keeling NJ, Klein TE, Whirl-Carrillo M, Pratt VM, Hoffman JM. Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics. 2018;19(10):847–860. doi:10.2217/pgs-2018-0028
   PubMed Web of Science ®Google Scholar
• Kalman LV, Agúndez J, Appell ML, et al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin Pharmacol Ther. 2016;99(2):172–185. doi:10.1002/cpt.280
   PubMed Web of Science ®Google Scholar
• Brouwer J, Nijenhuis M, Soree B, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. Eur J Hum Genet. 2021;30(10):1114–1120. doi:10.1038/s41431-021-01004-7
   PubMed Web of Science ®Google Scholar
• FDA. Table of pharmacogenomic biomarkers in drug labeling. Available from: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling. Accessed May 26, 2023.
   Google Scholar
• Lemke AA, Hutten Selkirk CG, Glaser NS, et al. Primary care physician experiences with integrated pharmacogenomic testing in a community health system. Per Med. 2017;14(5):389–400. doi:10.2217/pme-2017-0036
   PubMed Web of Science ®Google Scholar
• Luzum JA, Pakyz RE, Elsey AR, et al. The pharmacogenomics research network translational pharmacogenetics program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems. Clin Pharmacol Ther. 2017;102(3):502–510. doi:10.1002/cpt.630
   PubMed Web of Science ®Google Scholar
• Kapoor R, Tan-Koi WC, Teo YY. Role of pharmacogenetics in public health and clinical health care: a SWOT analysis. Eur J Hum Genet. 2016;24(12):1651–1657. doi:10.1038/ejhg.2016.114
   PubMed Web of Science ®Google Scholar
• Plöthner M, Ribbentrop D, Hartman JP, Frank M. Cost-effectiveness of pharmacogenomic and pharmacogenetic test-guided personalized therapies: a systematic review of the approved active substances for personalized medicine in Germany. Adv Ther. 2016;33(9):1461–1480. doi:10.1007/s12325-016-0376-8
   PubMed Web of Science ®Google Scholar
• Brown LC, Lorenz RA, Li J, Dechairo BM. Economic utility: combinatorial pharmacogenomics and medication cost savings for mental health care in a primary care setting. Clin Ther. 2017;39(3):592–602.e1. doi:10.1016/j.clinthera.2017.01.022
   PubMed Web of Science ®Google Scholar
• Karamperis K, Koromina M, Papantoniou P, et al. Economic evaluation in psychiatric pharmacogenomics: a systematic review. Pharmacogenomics J. 2021;21(4):533–541. doi:10.1038/s41397-021-00249-1
   PubMed Web of Science ®Google Scholar
• Fagerness J, Fonseca E, Hess GP, et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014;20(5):e146–e56.
   PubMed Web of Science ®Google Scholar
• Rahma AT, Elsheik M, Ali BR, et al. Knowledge, attitudes, and perceived barriers toward genetic testing and pharmacogenomics among healthcare workers in the United Arab Emirates: a cross-sectional study. J Pers Med. 2020;10(4):216. doi:10.3390/jpm10040216
   PubMed Web of Science ®Google Scholar
• Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians’ knowledge of and experience with pharmacogenetic testing. Clin Genet. 2012;82(4):388–394. doi:10.1111/j.1399-0004.2012.01908.x
   PubMed Web of Science ®Google Scholar
• Bonter K, Desjardins C, Currier N, Pun J, Ashbury FD. Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open. 2011;1(1):e000110. doi:10.1136/bmjopen-2011-000110
   PubMed Web of Science ®Google Scholar
• Owusu-Obeng A, Weitzel KW, Hatton RC, et al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy. 2014;34(10):1102–1112. doi:10.1002/phar.1481
   PubMed Web of Science ®Google Scholar
• Bain KT, Knowlton CH, Matos A. Cost avoidance related to a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly. Pharmacogenomics. 2020;21(10):651–661. doi:10.2217/pgs-2019-0197
   PubMed Web of Science ®Google Scholar
• Mills R, Haga SB. Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. Pharmacogenomics. 2013;14(8):957–968. doi:10.2217/pgs.13.76
   PubMed Web of Science ®Google Scholar
• McCullough KB, Formea CM, Berg KD, et al. Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ. 2011;75(3):51. doi:10.5688/ajpe75351
   PubMed Web of Science ®Google Scholar
• Nutescu EA, Drozda K, Bress AP, et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy. 2013;33(11):1156–1164. doi:10.1002/phar.1329
   PubMed Web of Science ®Google Scholar
• ISPG. Genetic testing and psychiatric disorder. Available from: https://ispg.net/genetic-testing-statement/. Accessed May 26, 2023.
   Google Scholar
• Haga SB, Mills R. A review of consent practices and perspectives for pharmacogenetic testing. Pharmacogenomics. 2016;17(14):1595–1605. doi:10.2217/pgs-2016-0039
   PubMed Web of Science ®Google Scholar
• Hoop JG, Lapid MI, Paulson RM, Roberts LW. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 “early adopting” departments of psychiatry. J Clin Psychiatry. 2010;71(6):745–753. doi:10.4088/JCP.08m04695whi
   PubMed Web of Science ®Google Scholar
• Payne K, Fargher EA, Roberts SA, et al. Valuing pharmacogenetic testing services: a comparison of patients’ and health care professionals’ preferences. Value Health. 2011;14(1):121–134. doi:10.1016/j.jval.2010.10.007
   PubMed Web of Science ®Google Scholar
• Bradbury AR, Patrick-Miller L, Domchek S. Multiplex genetic testing: reconsidering utility and informed consent in the era of next-generation sequencing. Genet Med. 2015;17(2):97–98. doi:10.1038/gim.2014.85
   PubMed Web of Science ®Google Scholar
• Byrne D. A worked example of Braun and Clarke’s approach to reflexive thematic analysis. Qual Quant. 2022;56(3):1391–1412. doi:10.1007/s11135-021-01182-y
   Google Scholar
• Dunnenberger HM, Biszewski M, Bell GC, et al. Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. Am J Health Syst Pharm. 2016;73(23):1956–1966. doi:10.2146/ajhp160072
   PubMed Web of Science ®Google Scholar